Research Analysts Issue Forecasts for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Axsome Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($0.41) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

A number of other research analysts have also weighed in on AXSM. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday. Robert W. Baird raised their price target on Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a report on Tuesday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Oppenheimer began coverage on Axsome Therapeutics in a research report on Tuesday, June 3rd. They set an "outperform" rating and a $185.00 target price for the company. Finally, Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a report on Tuesday, April 29th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $172.80.

Axsome Therapeutics Price Performance

NASDAQ AXSM traded up $0.04 on Tuesday, reaching $109.91. The company had a trading volume of 704,336 shares, compared to its average volume of 691,870. The stock has a market capitalization of $5.41 billion, a PE ratio of -18.35 and a beta of 0.47. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm's 50 day moving average price is $105.94 and its 200 day moving average price is $106.81.

Insider Buying and Selling

In other news, COO Mark L. Jacobson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $103.45, for a total value of $2,069,000.00. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $598,251.35. This represents a 77.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the sale, the director now directly owns 50,387 shares of the company's stock, valued at $5,314,316.89. This represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,423 shares of company stock valued at $4,950,619. Company insiders own 22.30% of the company's stock.

Institutional Investors Weigh In On Axsome Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BVF Inc. IL raised its stake in shares of Axsome Therapeutics by 21.8% during the first quarter. BVF Inc. IL now owns 1,690,221 shares of the company's stock valued at $197,130,000 after acquiring an additional 302,157 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Axsome Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock valued at $77,228,000 after buying an additional 4,079 shares during the period. Invesco Ltd. raised its holdings in shares of Axsome Therapeutics by 23.8% in the first quarter. Invesco Ltd. now owns 857,001 shares of the company's stock valued at $99,952,000 after acquiring an additional 164,537 shares in the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 4.5% in the first quarter. Wellington Management Group LLP now owns 703,279 shares of the company's stock worth $82,023,000 after acquiring an additional 30,122 shares during the period. Finally, Hood River Capital Management LLC lifted its stake in Axsome Therapeutics by 3.2% in the fourth quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock worth $54,555,000 after acquiring an additional 19,701 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.